ALSO NOTED: Nexavar OK'd for use against liver cancer; Japan's Olympus to buy Gyrus in $1.9 billion deal;

> Bayer and Onyx Pharmaceuticals got the FDA's nod to market Nexavar to treat liver cancer; the drug already is used against kidney cancer. Report

> Surgical equipment maker Gyrus recommended that its shareholders accept a $1.9 billion cash tender offer from Olympus, the Japanese camera company. Report

> Schering-Plough has wrapped up its acquisition of Organon BioSciences. Report

> Sales of over-the-counter cold meds for kids have fallen sharply since an FDA panel concluded they shouldn't be used in children younger than 6. Report

> India's Plethico Pharma is buying U.S.-based Natrol, a manufacturer and marketer of nutritional products, for $80.7 million. Report

> A Dallas whistleblower has implicated a multitude of surgical suppliers in a Medicare-fraud suit just unsealed in federal court. Report

And Finally... The much talked-about Baby Boomer generation is heading into their 50s--and they're looking to biotechnology to not only to extend their lives, but to make their later years better. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.